{
  "ticker": "IVX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975328",
  "id": "02975328",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1423",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mcyj9xnbjzd4.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Highlights**  \n- **Clinical Trials Progress**:  \n  - Phase I/II non-melanoma skin cancer (NMSC) trial completed first six patients with **no adverse events** and **early efficacy signals**.  \n  - **INV043 demonstrated fluorescence under violet light**, supporting potential as a diagnostic tool.  \n  - **Anogenital cancer trial** advancing with $20K grant from CSSANZ Foundation; Peter Mac preparing approval submission.  \n\n#### **Capital Raising & Cash Position**  \n- **Loyalty Option Entitlement Offer**: Fully underwritten, raised **~$1M (before costs)**; potential for **~$16M** if all options exercised.  \n- **Cash Balance**: **$850K** as of 30 June 2025 (down from $1.4M in prior quarter).  \n- **Cash Burn**:  \n  - **Operating outflow**: $725K (R&D: $262K; admin: $463K).  \n  - **Funding runway**: ~1.17 quarters (post-receipt of Entitlement Offer proceeds).  \n\n#### **Debt & Financing**  \n- **Partial repayment** to The Lind Partners; ~$850K balance may be settled in cash/shares.  \n\n---  \n*Summary tailored to material trading/capital markets factors; excludes operational commentary.*",
  "usage": {
    "prompt_tokens": 5033,
    "completion_tokens": 294,
    "total_tokens": 5327,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T04:28:26.292695"
}